BioAtla, Inc. (BCAB)

NASDAQ: BCAB · IEX Real-Time Price · USD
4.09
-0.05 (-1.21%)
At close: Feb 7, 2023, 4:00 PM
4.03
-0.06 (-1.47%)
After-hours: Feb 7, 2023, 7:30 PM EST
-1.21%
Market Cap 188.59M
Revenue (ttm) n/a
Net Income (ttm) -102.33M
Shares Out 46.11M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 332,033
Open 4.15
Previous Close 4.14
Day's Range 4.02 - 4.31
52-Week Range 2.01 - 12.15
Beta 0.63
Analysts Buy
Price Target 26.67 (+552.08%)
Earnings Date Mar 7, 2023

About BCAB

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 56
Stock Exchange NASDAQ
Ticker Symbol BCAB
Full Company Profile

Financial Performance

In 2021, BioAtla's revenue was $250,000, a decrease of -41.72% compared to the previous year's $429,000. Losses were -$95.40 million, 166.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price forecast is $26.67, which is an increase of 552.08% from the latest price.

Price Target
$26.67
(552.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

2 weeks ago - Barrons

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

1 month ago - GlobeNewsWire

Viatris Announces Appointments of Scott A. Smith and Elisha W.

Directors Neil Dimick and Ian Read Retire PITTSBURGH , Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W.

Other symbols: VTRS
1 month ago - PRNewsWire

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

1 month ago - GlobeNewsWire

Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

2 months ago - Zacks Investment Research

Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

3 months ago - Zacks Investment Research

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 Undifferentiated Pleomorphic Sarc...

5 months ago - PRNewsWire

BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

6 months ago - GlobeNewsWire

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

6 months ago - GlobeNewsWire

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

6 months ago - GlobeNewsWire

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

8 months ago - GlobeNewsWire

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –

9 months ago - GlobeNewsWire

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and...

10 months ago - GlobeNewsWire

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

SAN DIEGO, March 1, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

1 year ago - PRNewsWire

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

Other symbols: BMY
1 year ago - PRNewsWire

BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today ann...

1 year ago - PRNewsWire

BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

1 year ago - PRNewsWire

BioAtla Announces Private Placement of 2.7 Million Shares

SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therape...

1 year ago - PRNewsWire

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update

SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

1 year ago - PRNewsWire